Ciliary neurotrophic factor

Drug Profile

Ciliary neurotrophic factor

Latest Information Update: 09 Sep 1997

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fidia Farmaceutici; Roche Palo Alto LLC
  • Developer Roche Palo Alto LLC
  • Class Eye disorder therapies; Obesity therapies
  • Mechanism of Action Ciliary neurotrophic factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis

Most Recent Events

  • 09 Sep 1997 Dompe Biotec has terminated the licensing agreement with Fidia for ciliary neurotrophic factor in Italy
  • 11 Feb 1997 A study has been added to the adverse events section
  • 23 May 1995 Dompe Biotec is a licensee for ciliary neurotrophic factor in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top